$599

Novo Partners for Oral Drug Discovery; Bayer’s Kerendia Receives T1DM FDA Label Expansion; AbbVie’s Allergan Skincare + AOM Data; Roche Opens Boston CVRM Innovation Center

A series of cardiometabolic-related news items has been observed from Novo/Orbis, Bayer, AbbVie/Allergan Aesthetics, and Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here